Discussion
TEAEs
ONCHOCERCIASIS, WORMS, MEDICAL COMPLICATION
This is the first evaluation of the safety and tolerability of moxidectin in combination with albendazole (with or without DEC) for the treatment of LF in people with Mild to moderate systemic TEAEs are common immediately following LF treatment, and these are primarily related to host responses to dying Mf. They generally occur in the first 24–48 hours after treatment and resolve in 1–2 days [While albendazole affects the viability and reproductive capacity of adult filarial worms, it does not rapidly kill Mf or adult worms, and it does not commonly cause TEAEs [Limitations of our study include the small sample size per arm, limited enrollment of women and the lack of children. Prior studies have observed different frequencies of TEAEs between men and women treated for LF [Another limitation of the study was our exclusion of some individuals who would normally be included in MDA. In this study we excluded those with onchocerciasis, since it is a contraindication to receiving DEC. We excluded persons >70 years old to reduce the risk of loss to follow-up due to frailty or other medical complications over the course of three years of follow up. This, and the small size of the study, have some limiting effect on the generalizability of our findings. However, it is unlikely that inclusion of these groups would have significantly altered the results, as moxidectin has previously been shown to be safe in individuals with onchocerciasis [In conclusion, moxidectin combination treatments for LF were safe and well tolerated in this study. Moxidectin combination treatments seem to have the same TEAE profile as ivermectin combinations that are widely used in MDA programs to eliminate LF. Many areas in Africa are co-endemic for LF and onchocerciasis, and moxidectin is more effective than ivermectin for clearing 